IL243425A0 - Formulations and methods based on antibodies - Google Patents
Formulations and methods based on antibodiesInfo
- Publication number
- IL243425A0 IL243425A0 IL243425A IL24342515A IL243425A0 IL 243425 A0 IL243425 A0 IL 243425A0 IL 243425 A IL243425 A IL 243425A IL 24342515 A IL24342515 A IL 24342515A IL 243425 A0 IL243425 A0 IL 243425A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- antibody formulations
- antibody
- formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361843011P | 2013-07-04 | 2013-07-04 | |
| US201461979886P | 2014-04-15 | 2014-04-15 | |
| PCT/IB2014/062806 WO2015001504A2 (en) | 2013-07-04 | 2014-07-03 | Antibody formulations and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL243425A0 true IL243425A0 (en) | 2016-03-31 |
Family
ID=51355583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243425A IL243425A0 (en) | 2013-07-04 | 2015-12-31 | Formulations and methods based on antibodies |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10513555B2 (enExample) |
| EP (2) | EP3524264A1 (enExample) |
| JP (3) | JP6404338B2 (enExample) |
| KR (1) | KR20160030247A (enExample) |
| CN (1) | CN105492019B (enExample) |
| AU (1) | AU2014285719A1 (enExample) |
| CA (1) | CA2917097C (enExample) |
| CL (1) | CL2015003801A1 (enExample) |
| CU (2) | CU20170039A7 (enExample) |
| ES (1) | ES2704440T3 (enExample) |
| IL (1) | IL243425A0 (enExample) |
| MX (1) | MX2016000201A (enExample) |
| PE (1) | PE20160868A1 (enExample) |
| PH (1) | PH12015502788A1 (enExample) |
| RU (1) | RU2016103079A (enExample) |
| SG (1) | SG11201510601TA (enExample) |
| WO (1) | WO2015001504A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230065T1 (hr) | 2011-10-28 | 2023-03-03 | Prothena Biosciences Limited | Humanizirana protutijela koja prepoznaju alfa-sinuklein |
| SG11201404321YA (en) | 2012-01-27 | 2014-08-28 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| MA42613A (fr) | 2015-08-13 | 2018-06-20 | Amgen Inc | Filtration en profondeur chargée de protéines de liaison à un antigène |
| MX395336B (es) * | 2015-09-28 | 2025-03-25 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. |
| CN105127166A (zh) * | 2015-09-29 | 2015-12-09 | 中国华能集团清洁能源技术研究院有限公司 | 行走组件及具有其的光伏组件清洁装置 |
| CN109415440B (zh) * | 2016-06-27 | 2022-12-06 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
| MA46836A (fr) | 2016-11-15 | 2019-09-25 | H Lundbeck As | Agents, utilisations et procédés pour le traitement d'une synucléinopathie |
| EP3555127B1 (en) | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EA201991720A1 (ru) | 2017-02-17 | 2020-01-20 | Бристол-Маерс Сквибб Компани | Антитела к альфа-синуклеину и их применения |
| JP2021502955A (ja) * | 2017-09-28 | 2021-02-04 | プロセナ・バイオサイエンシズ・リミテッド | シヌクレイン病の治療のための投与レジメン |
| US20190153102A1 (en) * | 2017-09-28 | 2019-05-23 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| JP6831861B2 (ja) | 2019-01-25 | 2021-02-17 | 株式会社Ｇｒｉｎ | 歯科用測定器具、測定方法、及びアタッチメント器具 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| EP3786174A1 (en) * | 2019-08-27 | 2021-03-03 | Ichnos Sciences SA | Methods for antibody purification |
| GB2587228B (en) * | 2019-09-20 | 2021-10-27 | Protein Ark Ltd | Biological sample purification apparatus, use of the same, and systems comprising the same |
| WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
| KR20230086674A (ko) | 2020-09-10 | 2023-06-15 | 프로테나 바이오사이언시즈 리미티드 | 파킨슨 질환의 치료 |
| CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
| CA3230055A1 (en) | 2021-09-16 | 2023-03-23 | Josefine Nielsen Soderberg | Compositions and methods for treating synucleinopathies |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JP2000510813A (ja) | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Ｉｌ−１２用処方 |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| DE60045319D1 (de) | 1999-02-05 | 2011-01-13 | Samsung Electronics Co Ltd | Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| DE60323474D1 (de) | 2002-04-09 | 2008-10-23 | Flamel Tech Sa | Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin |
| EP1531864A4 (en) | 2002-05-13 | 2006-08-23 | Alexion Pharma Inc | HUMANIZED ANTIBODIES TO THE VENEZOLAN HORSEMEN ENZEPHALITIS VIRUS |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| ES2293096T3 (es) | 2002-11-29 | 2008-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
| AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL1820022T3 (pl) | 2004-11-10 | 2009-11-30 | Boehringer Ingelheim Pharma | Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika |
| CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| WO2007075283A2 (en) * | 2005-12-06 | 2007-07-05 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
| NZ574188A (en) | 2006-07-14 | 2012-05-25 | Ac Immune Sa | Humanized antibody against amyloid beta |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| SG178804A1 (en) | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
| JP5467415B2 (ja) | 2007-03-02 | 2014-04-09 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | タンパク質製造の改良 |
| SI2132230T1 (sl) | 2007-03-22 | 2014-07-31 | Genentech, Inc. | Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE |
| MX2009010179A (es) * | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| WO2009070642A1 (en) * | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| ES2511844T3 (es) | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Formulación de anticuerpo |
| PT2237803E (pt) | 2007-12-28 | 2015-10-16 | Prothena Biosciences Ltd | Tratamento e profilaxia da amiloidose |
| DK2282758T3 (en) | 2008-04-29 | 2019-02-25 | Bioarctic Ab | ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS |
| WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| NZ623910A (en) | 2009-07-28 | 2016-06-24 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2519537A4 (en) | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | CLEANING PROTEINS |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| US9028830B2 (en) | 2010-04-08 | 2015-05-12 | JN Biosciences, LLC | Antibodies to CD122 |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| MX343376B (es) | 2010-07-15 | 2016-11-03 | Adheron Therapeutics Inc | Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados. |
| SG10201508401TA (en) * | 2010-10-11 | 2015-11-27 | Abbvie Bahamas Ltd | Processes for purification of proteins |
| EP2673635A4 (en) | 2011-02-07 | 2015-08-12 | Neotope Biosciences Ltd | IMMUNOTHERAPY THROUGH APOE |
| WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
| US9845327B2 (en) | 2011-06-22 | 2017-12-19 | The General Hospital Corporation | Treatment of proteinopathies |
| WO2013003680A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| CA2853112C (en) * | 2011-10-25 | 2018-08-21 | Onclave Therapeutics Limited | Antibody formulations and methods |
| HRP20230065T1 (hr) | 2011-10-28 | 2023-03-03 | Prothena Biosciences Limited | Humanizirana protutijela koja prepoznaju alfa-sinuklein |
| AR088579A1 (es) | 2011-10-31 | 2014-06-18 | Genentech Inc | Formulaciones de anticuerpos |
| SG11201404321YA (en) | 2012-01-27 | 2014-08-28 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| RU2711552C2 (ru) | 2012-08-29 | 2020-01-17 | Ф. Хоффманн-Ля Рош Аг | Шаттл для гематоэнцефалического барьера |
| US8925815B2 (en) | 2012-09-05 | 2015-01-06 | Symbol Technologies, Inc. | Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2014
- 2014-07-02 US US14/322,797 patent/US10513555B2/en active Active
- 2014-07-03 RU RU2016103079A patent/RU2016103079A/ru not_active Application Discontinuation
- 2014-07-03 EP EP18212531.0A patent/EP3524264A1/en active Pending
- 2014-07-03 SG SG11201510601TA patent/SG11201510601TA/en unknown
- 2014-07-03 PE PE2015002708A patent/PE20160868A1/es not_active Application Discontinuation
- 2014-07-03 AU AU2014285719A patent/AU2014285719A1/en not_active Abandoned
- 2014-07-03 MX MX2016000201A patent/MX2016000201A/es unknown
- 2014-07-03 JP JP2016522950A patent/JP6404338B2/ja active Active
- 2014-07-03 CN CN201480047476.9A patent/CN105492019B/zh active Active
- 2014-07-03 CA CA2917097A patent/CA2917097C/en active Active
- 2014-07-03 WO PCT/IB2014/062806 patent/WO2015001504A2/en not_active Ceased
- 2014-07-03 CU CUP2017000039A patent/CU20170039A7/es unknown
- 2014-07-03 KR KR1020167003163A patent/KR20160030247A/ko not_active Withdrawn
- 2014-07-03 EP EP14752412.8A patent/EP3016677B1/en active Active
- 2014-07-03 ES ES14752412T patent/ES2704440T3/es active Active
-
2015
- 2015-12-16 PH PH12015502788A patent/PH12015502788A1/en unknown
- 2015-12-31 CL CL2015003801A patent/CL2015003801A1/es unknown
- 2015-12-31 IL IL243425A patent/IL243425A0/en unknown
-
2016
- 2016-01-04 CU CUP2016000001A patent/CU20160001A7/es unknown
-
2018
- 2018-09-12 JP JP2018170393A patent/JP6854266B2/ja active Active
-
2019
- 2019-11-01 US US16/672,330 patent/US20200140534A1/en not_active Abandoned
-
2020
- 2020-10-23 JP JP2020177954A patent/JP2021020941A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2704440T3 (es) | 2019-03-18 |
| EP3524264A1 (en) | 2019-08-14 |
| JP2019011339A (ja) | 2019-01-24 |
| EP3016677B1 (en) | 2018-12-19 |
| CU20170039A7 (es) | 2017-06-05 |
| EP3016677A2 (en) | 2016-05-11 |
| CA2917097A1 (en) | 2015-01-08 |
| JP2016534052A (ja) | 2016-11-04 |
| PE20160868A1 (es) | 2016-09-24 |
| JP6854266B2 (ja) | 2021-04-07 |
| CU20160001A7 (es) | 2016-08-31 |
| WO2015001504A2 (en) | 2015-01-08 |
| WO2015001504A3 (en) | 2015-08-06 |
| PH12015502788A1 (en) | 2016-03-21 |
| AU2014285719A1 (en) | 2016-01-21 |
| JP2021020941A (ja) | 2021-02-18 |
| HK1223544A1 (zh) | 2017-08-04 |
| US10513555B2 (en) | 2019-12-24 |
| US20150079074A1 (en) | 2015-03-19 |
| CA2917097C (en) | 2022-05-03 |
| CN105492019A (zh) | 2016-04-13 |
| RU2016103079A (ru) | 2017-08-07 |
| MX2016000201A (es) | 2016-05-31 |
| SG11201510601TA (en) | 2016-01-28 |
| US20200140534A1 (en) | 2020-05-07 |
| KR20160030247A (ko) | 2016-03-16 |
| JP6404338B2 (ja) | 2018-10-10 |
| CN105492019B (zh) | 2020-02-11 |
| CL2015003801A1 (es) | 2016-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202005525B (en) | Antibody formulations | |
| IL261743B (en) | and their uses 33–il antibodies against | |
| IL261547B (en) | Antibodies against pesidine and their uses | |
| SG11201510601TA (en) | Antibody formulations and methods | |
| IL244712B (en) | Anti- pdl1 antibody compositions | |
| IL245040A0 (en) | Antibodies against pdgfr-beta and their uses | |
| IL240517A0 (en) | Antibodies against b7–h4 and immunoconjugates | |
| IL243974A0 (en) | Antibodies against -prlr and uses | |
| ZA201508896B (en) | Anti-c10orf54 antibodies and uses thereof | |
| SG10201709715RA (en) | Anti-b7-h5 antibodies and their uses | |
| SG11201509116VA (en) | Anti-tweakr antibodies and uses thereof | |
| PT3480215T (pt) | Anticorpo anti-her2 e seu conjugado |